Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Mergers & Acquisitions

Business Roundup

April 12, 2019 | A version of this story appeared in Volume 97, Issue 15

 

Tokuyama plans to build a facility in Zhejiang Province, China, for high-purity isopropyl alcohol and tetramethylammonium hydroxide, a photoresist developer. The Japanese firm plans to sell the products to China’s semiconductor industry.

DuPont has opened an aerospace technology center in Valley View, Ohio, where it makes Vespel brand polyimide. The center will improve collaboration with commercial and military aerospace customers around the world, DuPont says.

Evonik Industries says it will expand production of transparent nylons at its facility in Marl, Germany. To be completed in early 2020, the project will double output, the firm says.

Dow and BioLogiQ are collaborating to find synergies between Dow’s polyethylene and BioLogiQ’s plant-based resin. The firms will evaluate combinations of the resins at Dow’s development center in Freeport, Texas.

BASF will expand capacity for sodium methylate at its plant in Guaratinguetá, ­Brazil, by one-third to 80,000 metric tons per year. The chemical is used to convert triglycerides into biodiesel.

AgomAb Therapeutics, a Belgian start-up, has raised about $23.5 million in series A financing to develop antibodies for tissue regeneration. The therapies are mimics of a protein called hepatocyte growth factor, which is involved in antifibrosis pathways.

Charles RiverLaboratories and CHDI Foundation have extended by 5 years a Huntington’s disease drug discovery collaboration. Charles River will supply crystallography, computational chemistry, and other services.

Novo Nordisk will spend close to $100 million to upgrade and expand its diabetes treatment facilities in Kalundborg, Denmark. The site manufactures around half the world’s insulin, the company says.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.